Well poised to capture global biosimilars opportunity The biologics segment (28% of FY19 in total revenues) includes biosimilars, encompassing Rh-insulin, insulin analogs, monoclonal antibodies & recombinant proteins. The company has invested heavily in this space in the last two to three years. The progress has been encouraging with approvals and launches in the US, EU, Japan, Australia and emerging markets. We...